Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by A. Falcone
VP11-2021: Trifluridine/tipiracil plus bevacizumab vs capecitabine plus bevacizumab as first line treatment for patients with metastatic colorectal cancer (mCRC) ineligible for intensive therapy: The phase III randomized SOLSTICE study
Background Based on the results of the phase 2 TASCO1 trial, this study was conducted in patients with previously untreated unresectable mCRC not eligible to receive standard doublet regimens with oxaliplatin or irinotecan due to age, performance status, comorbidities or non-clinical reasons (low tumour burden, patient's choice, others).
Integrated safety summary (ISS) for trifluridine/tipiracil (TAS-102)
Background: Efficacy and safety of trifluridine/tipiracil (FTD/TPI; TAS-102) in patients (pts) with metastatic colorectal cancer (mCRC) refractory/intolerant to standard therapies were evaluated in the phase 3 RECOURSE trial; enrollment criteria included ?2 prior lines of standard chemotherapy. RECOURSE showed significant improvement in overall survival (OS; hazard ratio [HR] = 0.68) and progression-free survival (PFS; HR = 0.48) with FTD/TPI vs placebo (pbo); both P < 0.0001.
Characteristics of patients (pts) with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) who had progression-free survival (PFS) >4 months (m): Subgroup analysis of the phase 3 CORRECT trial
Background: In CORRECT, REG significantly improved overall survival and PFS vs placebo in pts with treatment-refractory mCRC. We did a retrospective, exploratory subgroup analysis of REG-treated pts in CORRECT with PFS >4 m (long PFS) and ?4 m (short PFS). Methods: Pts with pretreated mCRC were randomized 2:1 to REG 160 mg or placebo QD for 3 weeks on/1 week off until disease progression, death, or unacceptable toxicity. PFS was the time from randomization to progression or death.
FOLFOXIRI plus bevacizumab (bev) followed by maintenance with bev alone or bev plus metronomic chemotherapy (metroCT) in metastatic colorectal cancer (mCRC): The phase II randomized MOMA trial
Background: Alternating induction and maintenance phases is a common strategy in mCRC. The optimal duration of induction and the optimal maintenance are open issues. MetroCT may represent a well-tolerated CT backbone for targeting angiogenesis and maximizing bev effect. Methods: MOMA (NCT02271464) is an Italian, no-profit, multicentric study.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with A.
Contact A., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack